STOCK MARKET BSE NSE

Covid: After Covaxin, ZyCov-D jabs, Belagavi hospital to conduct trials of Sanofi vaccine

Sanofi pharma company has already received permission from drug regulators to conduct clinical trials in India.

Published: 15th July 2021 12:45 AM  |   Last Updated: 15th July 2021 12:45 AM   |  A+A-

Jeevan Rekha Hospita

Jeevan Rekha Hospital. (Photo | Ashishkrishna, EPS)

Express News Service

BELAGAVI: Belagavi based Jeevan Rekha hospital has come up to conduct clinical trials of another Covid-19 vaccine. If everything goes as planned, the hospital will conduct the clinical trials of the vaccine developed by the French pharmaceutical company Sanofi in the next ten days. 

Sanofi has already received permission from drug regulators to conduct clinical trials in India. It has decided to conduct the trials in thirteen countries including India. 

Belagavi based Jeevan Rekha Hospital has been chosen for the trials and it will be among one of the ten places in India where the trials will be held. 

Jeevan Rekha hospital has already conducted clinical trials of the Covaxin vaccine developed by Bharat Biotech last year. About one thousand volunteers had participated in the trials which were held in three phases. 

Later, this hospital was also chosen by the Zydus Cadila company to get conduct the trials of their ZyCov-D vaccine. The hospital conducted the trials of this vaccine to ten girls and ten boys of the age category 12 to 18 years in the first dose in the month of May and scheduled for the second dose on the 28th day and the third dose on the 52nd day.  

The hospital officials have appealed to the people of Belagavi aged above 18 years to participate as volunteers in the clinical trials of the vaccine. However, only those people who have not taken doses of Covaxin or Covishield vaccine are eligible to participate in this trial. 

Speaking to The New Indian Express, Dr Amit Bhate, director of Jeevan Rekha hospital said 'This US-based vaccine is only for the adults. The number of volunteers required for the two-dose trials is yet to be informed. However, We have appealed the persons aged above 18 years and who are not vaccinated yet to enrol for this trial' he added.

ALSO WATCH:



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp